ArticleBMC cancer2026
Dabrafenib or trametinib in pediatric Langerhans cell histiocytosis with bone lesions: a retrospective efficacy and safety study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThis study evaluated the efficacy and safety of dabrafenib or trametinib in pediatric Langerhans cell histiocytosis (LCH) patients with skeletal involvement, for whom conventional therapies offer limited benefit.
methodsA single-center retrospective analysis was conducted on 30 children with pathologically confirmed, bone-involved LCH who received dabrafenib or trametinib due to severe, refractory, or chemotherapy-intolerant disease. Primary endpoints were imaging-based objective response rate (ORR) and disease control rate (DCR). Progression-free survival (PFS) was defined as time from targeted therapy initiation to disease progression (AD-Mixed/AD-Worse) or last follow-up, with AD-Better/AD-Stable considered disease control, including subgroup analysis by BRAF mutation status (V600E vs non-V600E).
resultsThe median age at diagnosis was 3.1 years with a male-to-female ratio of 2:1. The BRAF V600E mutation was detected in 27 patients (90.0%), with two patients harboring BRAF non-V600E mutations and one patient carrying a MAP2K1 mutation. The median duration of targeted therapy was 17.7 months. At last follow-up, 23.3% (7/30) achieved active disease-better status, and 60.0% (18/30) had active disease-stable status, resulting in an ORR of 23.3% and a DCR of 83.3%. All patients survived. Notably, patients with non-V600E driver mutations (BRAF class II or MAP2K1, cases 22, 26, 28) received MEK inhibitor therapy (trametinib) and derived clinical benefit, highlighting the importance of precise genomic characterization. Drug-related adverse events occurred in 20.0% (6/30) of patients, consisting of mild cutaneous toxicities (e.g., rash, paronychia).
conclusionsIn pediatric LCH with bone involvement, particularly in refractory or chemotherapy-intolerant cases, short- to intermediate-term targeted therapy with dabrafenib or trametinib achieved a high disease control rate (83.3%) with a favorable safety profile. Notably, patients with non-V600E driver mutations (BRAF class II or MAP2K1) derived clinical benefit from MEK inhibition, underscoring the importance of comprehensive genomic testing. These real-world findings support the use of targeted therapy in this challenging population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.